The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Safety and efficacy of golcadomide (CC-99282) in the treatment of R/R NHL
Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, shares some insights into the first results from a Phase I study investigating the use of golcadomide (CC-99282), a next-generation agent that induces targeted degradation of Ikaros/Aiolos transcription factors, in the treatment of patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NCT03930953). Dr Nastoupil highlights the benefits of current treatment options such as lenalidomide and compares this to the use of golcadomide, including cytotoxicity, activity, and response rates of patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
